Pemphigus vulgaris Treated with Rituximab and Intravenous Immunoglobulins
Authors:
M. Martincová; J. Šternberský; M. Tichý
Authors‘ workplace:
Klinika chorob kožních a pohlavních, Lékařská fakulta, Univerzita Palackého v Olomouci, Fakultní nemocnice Olomouc, přednosta MUDr. Martin Tichý, Ph. D.
Published in:
Čes-slov Derm, 100, 2025, No. 2, p. 83-89
Category:
Case interpretation
Overview
The authors present the case of a 72-year-old patient with severe pemphigus vulgaris. During systemic treatment (glucocorticoids, azathioprine, rituximab and intravenous immunoglobulins) serious complications occurred – azathioprine-induced bone marrow suppression, COVID-19 infection and two abdominal surgeries for diverticular perforation and ileus. Despite all the complications, the patient’s condition stabilized on a low dose of systemic corticosteroids. In the second part of the communication, the authors discuss the current therapeutic options for the treatment of pemphigus vulgaris.
Keywords:
intravenous immunoglobulins – rituximab – pemphigus vulgaris – recommended procedures
Sources
- ATZMONY, L., HODAK, E., LESHEM Y. A., et al. The role of adjuvant therapy in pemphigus: a systematic review and meta-analysis. J Am Acad Dermatol. 2015, 73(2), p. 264–271.
- BAUM, S., SCOPE, A., BARZILAI, A. et al. The role of IVIg treatment in severe pemphigus vulgaris. J Eur Acad Dermatol Venereol. 2006, 20 (5), p. 548– 552.
- BYSTRYN, J. C., RUDOLPH, J. L. Pemphigus. Lancet, 2005, 366(9479), p. 61–73.
- CHAMS-DAVATCHI, C., ESMAILI, N., DANESHPAZ- HOOH, M. et al. Randomized controlled open-label trial of four treatment regimens for pemphigus vulgaris. J Am Acad Dermatol., 2007, 57(4), p. 622– 628.
- EUROPEAN MEDICINES AGENCY (EMA) | MabThe-ra (n.d.). European Medicines Agency (EMA). Dostupné na www: https://www.ema.europa.eu/en/ medicines/human/EPAR/mabthera#email; cite 03.12.2024.
- HARMAN, K. E., BROWN, D., EXTON, L. S. et al. British Association of Dermatologists‘ guidelines for the management of pemphigus vulgaris. Br J Dermatol., 2017, 177(5), p. 1170–1201.
- HÉBERT, V., BOULARD, C., HOUIVET, E. et al. Large international validation of ABSIS and PDAI pemphigus severity scores. J. Invest. Derm., 2018, 139, p. 31–38.
- HERTL, M., JEDLICKOVA, H., KARPATI, S. et al. Pemphigus. S2 Guideline for diagnosis and treatment – guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV). J Eur Acad Dermatol Venereol, 2015, 29(3), p. 405–414.
- HOFFMANN, JOCHEN, H. O., ALEXANDER, H. ENK. “High-Dose Intravenous Immunoglobulin in Skin Autoimmune Disease.” Frontiers in imunology, 2019,10, p. 1090.
- IOANNIDES, D., LAZARIDOU, E., RIGOPOULOS, D. Pemphigus. J Eur Acad Dermatol Venereol., 2008, 22(12), p. 1478–1496.
- JEDLIČKOVÁ, H. Autoimunitní puchýřnatá onemocnění: část I. Pemfigus. Čes-slov Derm, 2022, 97, 4, p. 144–155.
- JOLY, P., BERNARD, P., BEDANE, C. at el. Centres de Référence des Maladies Bulleuses Auto-Immunes, Société Française de Dermatologie. Pemphigus: guidelines for the diagnosis and treatment [in French]. Ann Dermatol Venereol., 2011, 138(3), p. 252–258.
- JOLY, P., HORVATH, B., PATSATSI, Α. et al. Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the european academy of dermatology and venereology (EADV). J Eur Acad Dermatol Venereol., 2020, 34(9), p. 1900–1913.
Labels
Dermatology & STDs Paediatric dermatology & STDsArticle was published in
Czech-Slovak Dermatology
2025 Issue 2
Most read in this issue
- Coincidence of Psoriasis and Atopic Dermatitis. Case Report and Literature Review
- Pemphigus vulgaris Treated with Rituximab and Intravenous Immunoglobulins
- Zápis ze schůze výboru ČDS konané dne 4. 2. 2025
- Inflammatory Scar in Patients with Psoriasis